SuperworthProtalix BioTherapeutics profit margin PLX
Gross, operating and net profit as a share of revenue over the last twelve months, from 2012.
- Net margin, 12 months
- 23.5%
- Operating margin, 12 months
- 28.9%
- Net margin on a year earlier
- +13.4 pts
- Peer median
- 5.4%
Over the twelve months to Jun 30, 2026, Protalix BioTherapeutics kept 23.5% of its revenue as net profit, with an operating margin of 28.9% and a gross margin of 69.2%.
Five years earlier its net margin was −43.2%.
The median for 10 healthcare stocks of a similar size is 5.4%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −12.5% | −10.4% | 48.8% |
| FY2024 | 5.5% | 7.3% | 54.5% |
| FY2023 | 12.7% | 16.0% | 64.9% |
| FY2022 | −31.3% | −27.3% | 58.9% |
| FY2021 | −71.9% | −53.4% | 57.4% |
| FY2020 | −10.4% | 4.3% | 82.7% |
| FY2019 | −33.4% | −19.6% | 80.1% |
| FY2018 | −77.3% | −56.4% | 72.8% |
| FY2017 | n/a | n/a | 20.8% |
| FY2016 | n/a | n/a | 8.7% |
| FY2015 | n/a | n/a | 83.3% |
| FY2014 | n/a | n/a | 44.7% |
| FY2013 | n/a | n/a | 58.1% |
| FY2012 | −33.3% | −34.9% | 75.4% |
| FY2011 | n/a | n/a | 17.2% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 23.5% | +13.4 pts | 28.9% | |
| Q1 FY26 | 20.1% | +13.5 pts | 25.9% | |
| Q4 FY25 | −12.5% | −18.0 pts | −10.4% | |
| Q3 FY25 | 8.7% | +29.8 pts | 10.3% | |
| Q2 FY25 | 10.1% | +48.7 pts | 13.3% | |
| Q1 FY25 | 6.5% | −4.9 pts | 7.7% | |
| Q4 FY24 | 5.5% | −7.2 pts | 7.3% | |
| Q3 FY24 | −21.0% | −37.7 pts | −19.5% | |
| Q2 FY24 | −38.6% | −51.8 pts | −38.9% | |
| Q1 FY24 | 11.5% | +49.8 pts | 13.5% | |
| Q4 FY23 | 12.7% | +44.0 pts | 16.0% | |
| Q3 FY23 | 16.7% | +54.2 pts | 21.3% |
Against its peers
Companies in Healthcare nearest Protalix BioTherapeutics' size, closest first, today.
| Company | Profit margin |
|---|---|
| PLXProtalix BioTherapeutics | 23.5% |
| PDEXPro DEX | 17.6% |
| NATRNatures Sunshine Products | 3.7% |
| ELMDElectromed | 15.3% |
| UTMDUtah Medical Products | 29.0% |
| INFUInfuSystem | 6.0% |
| VMDViemed Healthcare | 4.8% |
| EMBCEmbecta | 8.6% |
| KEQUKewaunee Scientific | 3.0% |
| ICCCImmucell | 2.6% |
| ARVNArvinas | 2.9% |
| Peer median | 5.4% |
Where Protalix BioTherapeutics ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Protalix BioTherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.